Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carmen Franceschini Pascual

Internal Medicine Guayanilla, PR Medical Doctor

NPI 1174696827 CMS profile 852014

Munoz Rivera #152, Guayanilla, PR 00656

Open in the dashboard

General payments

$851

13 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carmen Franceschini Pascual of Guayanilla, PR is reported in the CMS Open Payments database as having received $851 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43 1
2024 General $209 2
2022 General $152 2
2021 General $109 2
2020 General $37 1
2019 General $300 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carmen Franceschini Pascual
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Carmen Franceschini Pascual were reported at $43. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Carmen Franceschini Pascual Internal Medicine median Middle half National median
2019 $300 $159 $48–$570 $163
2020 $37 $119 $33–$402 $114
2021 $109 $135 $37–$521 $132
2022 $152 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $209 $154 $47–$537 $164
2025 $43 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $289 3 payments
  2. Abbott Laboratories $209 2 payments
  3. GlaxoSmithKline, LLC. $120 1 payment
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $90 2 payments
  5. Janssen Pharmaceuticals, Inc $69 2 payments
  6. Genzyme Corporation $43 1 payment
  7. Boston Scientific Corporation $17 1 payment
  8. AstraZeneca Pharmaceuticals LP $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $851 13 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $289 3 payments
  2. MERLIN@HOME $209 2 payments
  3. SHINGRIX $120 1 payment
  4. LifeVest $90 2 payments
  5. XARELTO $69 2 payments
  6. General Therapies $17 1 payment
  7. BRILINTA $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

12,445

Median for Internal Medicine: 777

Drug cost

$584,645

Median for Internal Medicine: $73,373

Branded share of claims

23.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 153 $104,001
Synthroid Levothyroxine Sodium Brand 936 $64,488
Eliquis Apixaban Brand 63 $38,854
Jardiance Empagliflozin Brand 55 $34,188
Xarelto Rivaroxaban Brand 46 $30,296
Januvia Sitagliptin Phosphate Brand 39 $26,954
Tradjenta Linagliptin Brand 37 $24,766
Janumet Sitagliptin Phos/Metformin Hcl Brand 40 $22,695
Synjardy Empagliflozin/Metformin Hcl Brand 29 $18,903
Humulin 70-30 Insulin Nph Hum/Reg Insulin Hm Brand 171 $17,841

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record